Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs
2025 ASCO Annual Meeting
Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508).
The ASCO Post Staff
Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3).
The ASCO Post Staff
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemotherapy or nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (Abstract 3501).
The ASCO Post Staff
Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer (Abstract 1001).
The ASCO Post Staff
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
The ASCO Post Staff
Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract 5014).
